Arcus Biosciences Inc (RCUS) Stock: Understanding Its Underlying Value
H.C. Wainwright has recently initiated Arcus Biosciences Inc (RCUS) stock to Neutral rating, as announced on October 21, 2024, according to Finviz. Earlier, on October 8, 2024, Wells Fargo had initiated the stock to Overweight, setting a price target of $29. BofA Securities also initiated Neutral rating with a price target of $33. Additionally, Morgan […]
Arcus Biosciences Inc (RCUS) Stock: Unveiling Its Hidden Strengths
H.C. Wainwright has recently initiated Arcus Biosciences Inc (RCUS) stock to Neutral rating, as announced on October 21, 2024, according to Finviz. Earlier, on October 8, 2024, Wells Fargo had initiated the stock to Overweight, setting a price target of $29. BofA Securities also initiated Neutral rating with a price target of $33. Additionally, Morgan […]
What’s Behind the -8.47% Drop in Arcus Biosciences Inc (RCUS) Stock? Find Out Now!
H.C. Wainwright has recently initiated Arcus Biosciences Inc (RCUS) stock to Neutral rating, as announced on October 21, 2024, according to Finviz. Earlier, on October 8, 2024, Wells Fargo had initiated the stock to Overweight, setting a price target of $29. BofA Securities also initiated Neutral rating with a price target of $33. Additionally, Morgan […]
The Arcus Biosciences Inc Stock Thriller: Decoding the Mystery Behind RCUS’s Recent Movements
H.C. Wainwright has recently initiated Arcus Biosciences Inc (RCUS) stock to Neutral rating, as announced on October 21, 2024, according to Finviz. Earlier, on October 8, 2024, Wells Fargo had initiated the stock to Overweight, setting a price target of $29. BofA Securities also initiated Neutral rating with a price target of $33. Additionally, Morgan […]
Arcus Biosciences Inc (RCUS) Stock’s -0.09% Decrease This Year: What’s the Story?
Wells Fargo has recently initiated Arcus Biosciences Inc (RCUS) stock to Overweight rating, as announced on October 8, 2024, according to Finviz. Earlier, on November 18, 2022, BofA Securities had initiated the stock to Neutral, setting a price target of $33. Morgan Stanley also initiated Overweight rating with a price target of $40. Additionally, BTIG […]
What’s Driving Arcus Biosciences Inc (RCUS) Stock’s 7.11% Surge Over the Past Month?
Wells Fargo has recently initiated Arcus Biosciences Inc (RCUS) stock to Overweight rating, as announced on October 8, 2024, according to Finviz. Earlier, on November 18, 2022, BofA Securities had initiated the stock to Neutral, setting a price target of $33. Morgan Stanley also initiated Overweight rating with a price target of $40. Additionally, BTIG […]
How Does Arcus Biosciences Inc (RCUS) Stack Up Against Its Industry Peers?
BofA Securities has recently initiated Arcus Biosciences Inc (RCUS) stock to Neutral rating, as announced on November 18, 2022, according to Finviz. Earlier, on October 11, 2022, Morgan Stanley had initiated the stock to Overweight, setting a price target of $40. BTIG Research also resumed Buy rating with a price target of $57. Additionally, Berenberg […]
Why Did Arcus Biosciences Inc (RCUS) Stock See -0.41% Plunge in the Last 90 Days?
BofA Securities has recently initiated Arcus Biosciences Inc (RCUS) stock to Neutral rating, as announced on November 18, 2022, according to Finviz. Earlier, on October 11, 2022, Morgan Stanley had initiated the stock to Overweight, setting a price target of $40. BTIG Research also resumed Buy rating with a price target of $57. Additionally, Berenberg […]
Arcus Biosciences Inc’s Stock Drama: Could This Be a Game-Changer for RCUS Investors?
BofA Securities has recently initiated Arcus Biosciences Inc (RCUS) stock to Neutral rating, as announced on November 18, 2022, according to Finviz. Earlier, on October 11, 2022, Morgan Stanley had initiated the stock to Overweight, setting a price target of $40. BTIG Research also resumed Buy rating with a price target of $57. Additionally, Berenberg […]
Why Did BofA Securities Give Arcus Biosciences Inc (RCUS) Stock Neutral Rating?
BofA Securities has recently initiated Arcus Biosciences Inc (RCUS) stock to Neutral rating, as announced on November 18, 2022, according to Finviz. Earlier, on October 11, 2022, Morgan Stanley had initiated the stock to Overweight, setting a price target of $40. BTIG Research also resumed Buy rating with a price target of $$57. Additionally, Berenberg […]
